冬凌草抗肿瘤研究综述:植物学、植物化学与临床应用
本文系统综述冬凌草(Rabdosia rubescens)的植物学、民族药理、植物化学、抗肿瘤活性成分、机制及临床应用,检索1997至2024年文献,共识别50种抗肿瘤化合物,并总结其多途径抗肿瘤机制及临床辅助治疗证据。
要点
- 冬凌草含50种抗肿瘤化合物,以二萜类为主,冬凌草甲素和冬凌草乙素为已知活性成分。
- 冬凌草通过阻滞细胞周期、促凋亡、抑制迁移与血管生成、诱导铁死亡、逆转耐药和增强放疗敏感性抗肿瘤。
- 2020年版《中国药典》将冬凌草片列为癌症辅助治疗药物,临床研究显示其糖浆、片剂及热疗可提高生存率、降低复发率。
核心结论
- 冬凌草是具有抗肿瘤潜力的中药资源,其活性成分、机制及临床辅助治疗作用得到综述支持。
- 未来需超越冬凌草甲素和冬凌草乙素,探索更多活性抗肿瘤化合物,并开展结构修饰以发现新活性分子和关键抗肿瘤结构。
- 临床需研究冬凌草与其他中药在抗肿瘤复方中的相互作用,并开展经过伦理审查的大规模随机对照试验验证疗效。
研究设计与样本
- 系统检索PubMed、Web of Science和CNKI,关键词包括冬凌草、传统应用、抗肿瘤、植物化学、冬凌草甲素和临床应用等。
- 检索覆盖1997年至2024年发表的文献,纳入聚焦冬凌草或其活性成分抗肿瘤特性的原始研究或综述,排除非冬凌草应用的研究。
主要发现
- 冬凌草为唇形科多年生草本植物,主要分布于中国中部和南部,历史上用于治疗咽喉痛、咳嗽和痰多。
- 植物含二萜类、三萜类、甾体、黄酮类、酚酸、精油、氨基酸、生物碱和多糖等化合物,其中二萜类、三萜类、黄酮类和酚酸类最具活性。
- 综述识别50种具有抗肿瘤特性的化合物,包括34种二萜类、2种三萜类、7种黄酮类和7种酚酸类。
- 除冬凌草甲素和冬凌草乙素外,(20S)-11β,14β,20-三羟基-7α,20-环氧-ent-考烷-16-烯-15-酮和(20S)-11β,14β-二羟基-20-乙氧基-7α,20-环氧-ent-考烷-16-烯-15-酮显示显著抗肿瘤活性,归因于C-15羰基、C-1羟基和C-20乙氧基。
- 机制上,冬凌草通过阻滞肿瘤细胞周期、促进凋亡、抑制细胞迁移和血管生成、诱导铁死亡、逆转耐药和增强肿瘤细胞放射敏感性发挥抗肿瘤作用。
关键数值与推荐
- 2020年版《中国药典》将冬凌草片列为癌症辅助治疗药物。
- 综述共识别50种抗肿瘤化合物:34种二萜类、2种三萜类、7种黄酮类和7种酚酸类。
临床怎么用
- 冬凌草片可作为癌症辅助治疗药物,冬凌草糖浆、片剂和热疗可能有助于提高生存率和降低复发率。
- 冬凌草制剂临床主要用于扁桃体炎、咽炎和口腔炎。
- 临床需关注冬凌草与其他中药在抗肿瘤复方中的相互作用,以增强疗效并指导合理使用。
局限性
- 未来需探索冬凌草甲素和冬凌草乙素之外的更多活性抗肿瘤化合物。
- 需对关键成分进行结构修饰以发现新活性分子和 essential 抗肿瘤结构。
- 临床需开展经过伦理审查的大规模随机对照试验验证冬凌草治疗肿瘤的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese herbal medicine has unique advantages as anti-cancer drugs and adjuvant therapies. Rabdosia rubescens (Hemsl.) H. Hara (R. rubescens) is a traditional medicinal plant known for its anti-inflammatory, antioxidant, antibacterial, anti-angiogenic and antitumor properties. The antitumor activity of R. rubescens is widely recognized among the folk communities in Henan Province, China. AIM OF THE STUDY: This study reviews the botany, ethnopharmacology, phytochemistry, anti-tumor active ingredients, mechanisms, and clinical applications of R. rubescens, aiming to provide a comprehensive understanding for its use as an anti-cancer drug and adjuvant therapy. MATERIALS AND METHODS: We systematically searched the literature in PubMed, Web of Science, and CNKI using the following keywords: "Rabdosia rubescens", "Isodon rubescens", "traditional application", "anti-tumor", "phytochemistry", "anti-tumor active compounds", "oridonin" and "clinical application". The search covered publications from 1997 to 2024. Inclusion criteria included original studies or reviews focusing on the anti-tumor properties of R. rubescens or its active components. Exclusion criteria included studies related to non-R. rubescens applications. RESULTS: R. rubescens is a perennial herbaceous plant in the family Lamiaceae, mainly found in central and southern China. Historically, it has been used to treat conditions such as sore throat, cough, and excess phlegm. The plant contains various compounds, including diterpenes, triterpenes, steroids, flavonoids, phenolic acids, essential oils, amino acids, alkaloids, and polysaccharides, with diterpenes, triterpenes, flavonoids, and phenolic acids being the most active. This review identifies 50 compounds with anti-tumor properties, comprising 34 diterpenes, 2 triterpenes, 7 flavonoids, and 7 phenolic acids. Notably, besides oridonin and ponicidin, the ent-kaurane diterpenoids (20S)-11β,14β,20-trihydroxy-7α,20-epoxy-ent-kaur-16-en15-one and (20S)-11β,14β-dihydroxy-20-ethoxy7α,20-epoxy-ent-kaur-16-en-15-one demonstrate significant anti-tumor activity, attributed to their carbonyl group at C-15, hydroxyl group at C-1, and OEt group at C-20. Mechanistically, R. rubescens combats tumors by blocking the tumor cell cycle, promoting apoptosis, inhibiting cell migration and angiogenesis, inducing ferroptosis, reversing drug resistance, and enhancing radiosensitivity in tumor cells. Clinically, R. rubescens is available in various forms, including tablets, drops, syrups, capsules, and lozenges, and is primarily used for tonsillitis, pharyngitis, and stomatitis. According to the 2020 edition of the Pharmacopoeia of China, R. rubescens tablets are recognized as an adjuvant therapy for cancer. Clinical studies indicate that R. rubescens syrup, tablets, and thermal therapy can enhance cancer patient survival rates and lower tumor recurrence rates. CONCLUSIONS: Given its traditional and modern uses, active anti-tumor components, and mechanisms, R. rubescens is a promising resource in traditional Chinese medicine for anti-tumor therapy. To realize its full potential, future research should explore additional active anti-tumor compounds beyond oridonin and ponicidin. For these key components, studies should focus on structural modifications to identify new active molecules and essential anti-tumor structures. Clinically, it is important to investigate how R. rubescens interacts with other Chinese herbs in anti-tumor formulations to enhance treatment efficacy and guide appropriate clinical use. Furthermore, future studies should undergo ethical review and include larger-scale randomized controlled trials to validate the efficacy of R. rubescens in treating tumors, thereby promoting its role as an anti-tumor traditional Chinese medicine.
引用
- Gao S, Li J, Wang W, et al. Rabdosia rubescens (Hemsl.) H. Hara: A potent anti-tumor herbal remedy - Botany, phytochemistry, and clinical applications and insights. J Ethnopharmacol. 2024. PMID: 39631716. doi:10.1016/j.jep.2024.119200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。